MEDISTIM WKN: A0D9B1 ISIN: NO0010159684 Kürzel: MEDI Forum: Aktien Thema: Hauptdiskussion

Results for the third quarter 2022 Posted on 28. October 2022 by Medistim ASA Another strong quarter ending at MNOK 116.5 in sales (MNOK 102.1), up 14.0 %. YTD revenue ended at MNOK 350.1 (MNOK 314.5), up 11.3 % https://medistim.com/2022/10/results-for-the-third-quarter-2022/

Results for the Fourth Quarter and Preliminary Results for 2022 Posted on 1. March 2023 by Medistim ASA Another record quarter ending at MNOK 141.8 in sales (MNOK 112.7). Full-year revenue at MNOK 491.9 (MNOK 427.3) is also a new record, up 15.1 % https://medistim.com/2023/03/results-for-the-fourth-quarter-and-preliminary-results-for-2022/

🎈

In the second quarter, Medistim delivers a new record in quarterly sales revenues, reaching 144.9 MNOK. This represents a 5.5 % increase in NOK and a currency-neutral growth of 4.1% compared to Q2 of the previous year, which is the third highest quarter for sales to date. This performance aligns with our expectations for continuous growth improvement throughout the year. Reflecting on the disappointing EBIT margin of 16.4% in the fourth quarter of 2023 and the subsequent improvement to 24% in the first quarter, we are pleased to report that this positive profitability trajectory has continued into the second quarter, culminating in an EBIT margin at 28.5 %. .... In summary, it is important to consider the increased running costs resulting from the establishment of direct sales operations in China, Canada, and Sweden last year, as well as the implementation of a second shift in probe production. Despite these higher costs, we have successfully improved total sales growth and are seeing the EBIT margin return to historical levels. Medistim’s financial position remains robust, with an equity ratio of 80.4%, no interest-bearing debt, and a cash position of 107.1 MNOK following a dividend payout of 82.4 MNOK in May. 15th August, 2024 Kari E. Krogstad President & CEO https://www.medistim.com/investor-relations/financial-reports-and-presentations

Das Umsatzwachstum ist nicht mehr so hoch wie früher. Die Margen waren zurückgegangen. Scheint sich jetzt aber zu drehen. Unternehmen grundsätzlich solide...Denke, ich steige nächste Woche wieder ein.

Ich lege jetzt noch msl nach. Deutschland läuft auch. Langfristig ist das 1a.

https://medistim.com/2022/08/results-for-the-second-quarter-and-first-half-2022/

Ja, läuft weiterhin ganz ok... medistim.com/2022/02/results-for-the-fourth-quarter-and-preliminary-results-for-2021/ All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1). Currency neutral sales of own products increased by 38% for the quarter and 28% for the year.

Gab es was Neues dieses Jahr?

🧐

Zahlen hat es vor ein paar Tagen auch mal gegeben. Läuft weiter gut. Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%... Operating result (EBIT) for the quarter ended at MNOK 25.1 (MNOK 20.8) a 20.3% increase... This is the best operating result YTD September ever https://medistim.com/2021/10/results-for-the-third-quarter-2021/

Nee, die ist noch am Start und es gibt keinen Grund zu wechseln. Gute Nischen, die jeder braucht sind das beste im Aktienmarkt

Hat deine Frau hier etwa gekündigt, oder warum geht es hier runter ? 😉.... Hab ich zum Nachkaufen genutzt und meinen EK ein wenig erhöht..

Meine Frau tut alles, damit es weiter geht. Jeden Tag. Einfach eine gei.le Company bis rauf zur Chefin.

Sind ja sogar wegen Corona viele OPs verschoben worden. Potenzial ist also auch noch da.